Co-ordinated isolation of CD8 and CD4 T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy

Cytotherapy

Volumn 12, Issue 7, 2010, Pages 933-944

  Zandvliet, Maarten L ^a   Van Liempt, Ellis ^a   Jedema, Inge ^a   Veltrop Duits, Louise A ^a   Willemze, Roel ^a   Guchelaar, Henk Jan ^a   Falkenburg, J H Frederik ^a   Meij, Pauline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adoptive immunotherapy; cytomegalovirus reactivation; interferon based isolation; protein spanning peptide pools

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RO ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; GAMMA INTERFERON; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ARTICLE; BLOOD; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CELL SPECIFICITY; CELL STIMULATION; CYTOMEGALOVIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 77958008421     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903505822     Document Type: Article

References (44)

1. + T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202: 673-85.
2. Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev. 2003;17:259-64.
3. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-38.
4. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003;98:269-97.
5. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol. 2004;65:403-9.
6. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407-14.
7. Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by inter-feron-gamma enzyme-linked immunospot assay and fl ow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 2002;99:3830-7.
8. + T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8: 501-11.
9. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 2006;108:1406-12.
10. Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:687-92.
11. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93:248-56.
12. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.
13. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-86.
14. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-6.
15. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:707-14.
16. Meij P, Zandvliet ML, Van der Heiden PLJ, Jedema I, Van Egmond HM, Cox LMP, et al. Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation. EBMT [Abstract] www.congrex.ch/ebmt2007. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France. 2007.
17. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112:3974-81.
18. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-7.
19. Peggs KS, Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol. 2004;65:550-7.
20. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-22.
21. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397-406.
22. Rentenaar RJ, Gamadia LE, van DerHoek N, van Diepen FN, Boom R, Weel JF, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest. 2000;105:541-8.
23. + T cells in protection against CMV disease. Blood. 2003;101: 2686-92.
24. + T lymphocytes with cellular maturation. J Exp Med. 2006;203:2865-77.
25. +T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77: 5226-40.
26. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005; 201:1999-2010.
27. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-6.
28. Yao J, Bechter C, Wiesneth M, Harter G, Gotz M, Germeroth L, et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 2008;46:e96-105.
29. + T cells for adoptive immunotherapy. J Immunother. 2009;32:513-23.
30. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40:63-7.
31. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30:1676-82.
32. Kiecker F, Streitz M, Ay B, Cherepnev G, Volk HD, Volkmer-Engert R, et al. Analysis of antigen-specific T-cell responses with synthetic peptides: what kind of peptide for which purpose? Hum Immunol. 2004;65:523-36.
33. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105:2793-801.
34. Faber LM, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283-9.
35. Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004;103:630-8.
36. +T-cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol. 2006;146:203-10.
37. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-6.
38. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-82.
39. Villarino AV, Tato CM, Stumhofer JS, Yao Z, Cui YK, Hennighausen L, et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med. 2007;204:65-71.
40. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15:821-50.
41. Zandvliet ML, Falkenburg JHF, Kester MGD, de Ru AH, van Veelen PA, Willemze R, et al. Sequence dependent efficiency of cross-presentation in MHC class Irequires rational design of long synthetic peptides for vaccination or ex vivo activation. [Abstract] Blood. 2008;112:1330-1.
42. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, Kenter MJ, et al. Recycling MHC class Imolecules and endosomal peptide loading. Proc Natl Acad Sci USA. 1999;96:10326-31.
43. Groothuis TA, Neefjes J. The many roads to cross-presentation. J Exp Med. 2005;202:1313-18.
44. + T cells. J Biol Chem. 2009;284:9184-91.